US Bancorp DE decreased its stake in shares of Solventum Co. (NYSE:SOLV - Free Report) by 3.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 484,513 shares of the company's stock after selling 18,047 shares during the quarter. US Bancorp DE owned about 0.28% of Solventum worth $32,007,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently modified their holdings of the company. Hotchkis & Wiley Capital Management LLC acquired a new stake in Solventum in the 3rd quarter valued at $125,488,000. Trian Fund Management L.P. grew its position in Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company's stock valued at $496,842,000 after purchasing an additional 1,765,676 shares during the period. Point72 Asset Management L.P. acquired a new stake in Solventum in the 3rd quarter valued at $50,948,000. Nordea Investment Management AB grew its position in Solventum by 189.5% in the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company's stock valued at $43,902,000 after purchasing an additional 431,986 shares during the period. Finally, General American Investors Co. Inc. acquired a new stake in Solventum in the 3rd quarter valued at $14,456,000.
Several equities analysts have weighed in on SOLV shares. Piper Sandler raised their price objective on Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research note on Friday. Morgan Stanley raised their price objective on Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Wells Fargo & Company raised their price objective on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research note on Friday. Mizuho started coverage on Solventum in a research note on Wednesday, December 4th. They set a "neutral" rating and a $70.00 price objective on the stock. Finally, Bank of America raised their price objective on Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $74.71.
View Our Latest Stock Analysis on SOLV
NYSE SOLV opened at $79.56 on Monday. The stock has a market capitalization of $13.74 billion and a price-to-earnings ratio of 28.93. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The business's fifty day moving average is $72.51 and its 200-day moving average is $70.05.
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.